RNASET2 overexpression

News alerts, weekly reports and conference planners

Entrez ID:

RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	ABT-869 Sensitive: C3 – Early Trials BMC Cancer - 3 weeks (New C3) ABT-869 Sensitive : C3 BMC Cancer - 3wk	ABT-869 Sensitive: C3 – Early Trials BMC Cancer - 3 weeks ABT-869 Sensitive : C3 BMC Cancer - 3 weeks - (New C3)
RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	midostaurin Sensitive: C3 – Early Trials BMC Cancer - 3 weeks (New C3) midostaurin Sensitive : C3 BMC Cancer - 3wk	midostaurin Sensitive: C3 – Early Trials BMC Cancer - 3 weeks midostaurin Sensitive : C3 BMC Cancer - 3 weeks - (New C3)
RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	vinblastine Sensitive: C3 – Early Trials BMC Cancer - 3 weeks (New C3) vinblastine Sensitive : C3 BMC Cancer - 3wk	vinblastine Sensitive: C3 – Early Trials BMC Cancer - 3 weeks vinblastine Sensitive : C3 BMC Cancer - 3 weeks - (New C3)
RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	vorinostat Sensitive: C3 – Early Trials BMC Cancer - 3 weeks (New C3) vorinostat Sensitive : C3 BMC Cancer - 3wk	vorinostat Sensitive: C3 – Early Trials BMC Cancer - 3 weeks vorinostat Sensitive : C3 BMC Cancer - 3 weeks - (New C3)

Associations